Beam Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Beam Therapeutics CEO'su John Evans, Jan2017 tarihinde atandı, in görev süresi 9.42 yıldır. in toplam yıllık tazminatı $ 5.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13% maaş ve 87% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.95% ine doğrudan sahiptir ve bu hisseler $ 27.56M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 5.4 yıldır.
Anahtar bilgiler
John Evans
İcra Kurulu Başkanı
US$5.8m
Toplam tazminat
| CEO maaş yüzdesi | 12.98% |
| CEO görev süresi | 9.4yrs |
| CEO sahipliği | 1.0% |
| Yönetim ortalama görev süresi | 5.8yrs |
| Yönetim Kurulu ortalama görev süresi | 5.4yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 01
BEAM: Lung And Liver Gene Editing Progress Will Drive Future Repricing
Beam Therapeutics' blended analyst price target has inched lower by about $1 to roughly $39, as analysts factor in slightly higher discount rates and more moderate revenue growth assumptions. They are still highlighting supportive sector trends such as healthy biotech M&A, IPO activity, and a constructive FDA backdrop for earlier stage companies.Anlatı Güncellemesi • May 13
BEAM: Liver Editing Platform And Non Dilutive Funding Will Drive Future Repricing
Analysts have lifted their average price targets on Beam Therapeutics by low single digit dollars per share, citing updated expectations for revenue growth, profitability and long term P/E multiples following recent company updates, new program announcements such as BEAM-304, and non dilutive financing agreements. Analyst Commentary Recent research reports on Beam Therapeutics focus on how new clinical programs, financing arrangements and regulatory interactions could affect the company’s execution risk and potential equity value.Anlatı Güncellemesi • Apr 25
BEAM: Liver Editing Pipeline And Regulatory Momentum Will Drive Future Repricing
Beam Therapeutics' analyst price target increased by $4, with analysts pointing to Q4 results, progress on Sickle Cell Disease and AATD programs, new liver-directed initiatives such as BEAM-304, and non-dilutive financing as key supports for the revised outlook. Analyst Commentary Recent Street research around Beam Therapeutics has focused on the Q4 print, progress in Sickle Cell Disease and AATD, and the expansion of its liver targeted base editing programs, alongside the use of non dilutive financing to support the pipeline.Anlatı Güncellemesi • Apr 10
BEAM: FDA Alignment And Liver Programs Will Drive Future Upside Repricing
Analysts have nudged the fair value estimate for Beam Therapeutics higher to $51.20 from $50.27, citing a series of recent price target increases related to progress in its liver-targeted programs, Sickle Cell Disease plans, and non-dilutive financing support. Analyst Commentary Recent research coverage on Beam Therapeutics has centered on updated price targets, expanded liver-directed programs, progress in Sickle Cell Disease, and the use of non-dilutive financing to support potential commercialization efforts.Anlatı Güncellemesi • Mar 26
BEAM: FDA Alignment And Liver Programs Will Drive Future Repricing
Analysts have nudged their average price target for Beam Therapeutics slightly higher, supported by recent target increases across several firms that point to growing confidence in the company’s base editing pipeline, new liver programs, regulatory progress, and non dilutive financing, even as expectations for revenue growth are tempered and profit margin assumptions improve alongside a lower implied future P/E multiple. Analyst Commentary Recent research coverage on Beam Therapeutics clusters around higher price targets, new liver focused programs, regulatory updates, and fresh non dilutive financing, with most commentary tilting positive but still flagging execution and program risk.Anlatı Güncellemesi • Mar 12
BEAM: FDA Alignment And New Liver Programs Will Drive Future Repricing
Analyst price targets for Beam Therapeutics have moved higher recently, with several firms lifting their views into a roughly $26 to $75 range. They point to progress in sickle cell BLA plans, new liver-directed programs such as BEAM-304, and non-dilutive financing that supports ongoing pipeline development.
Yeni Anlatı • Mar 11
Liver Base Editing Platform Will Transform Rare Disease Treatment Over The Long Term
Catalysts About Beam Therapeutics Beam Therapeutics focuses on base editing therapies aimed at providing onetime genetic treatments for serious diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 27
Beam Therapeutics: Great Potential, But Patience Is Needed
Summary Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior efficacy in sickle cell disease, but commercial success hinges on overcoming conditioning protocol challenges and competing with Vertex/Crispr's head start. The liver-targeted BEAM-302 program demonstrates strong early clinical results and could establish a competitive moat, with pivotal data and BLA submission expected in 18–24 months. Robust cash position ($1.09B net) and Pfizer partnership mitigate dilution risk, but BEAM stock investors should expect volatility and a multi-year timeline to full value realization. Read the full article on Seeking AlphaAnlatı Güncellemesi • Feb 26
BEAM: FDA Program Alignment On Sickle Cell Will Drive Future Repricing
Analysts have raised their average price targets for Beam Therapeutics by a few dollars, reflecting progress on sickle cell regulatory plans, new liver-focused programs such as BEAM-304 for phenylketonuria, and recent non-dilutive financing that supports the broader clinical pipeline. Analyst Commentary Recent research updates show a cluster of higher price targets around Beam Therapeutics, with most commentary focusing on execution in sickle cell disease, progress in liver programs, and the new non dilutive financing structure.
Yeni Anlatı • Feb 25
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
Catalysts About Beam Therapeutics Beam Therapeutics develops base editing genetic medicines that aim to provide onetime treatments for serious diseases such as sickle cell disease, alpha-1 antitrypsin deficiency and phenylketonuria. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 12
BEAM: FDA Program Alignment And Upcoming Data Readout Will Drive Repricing
Analysts have modestly raised their price targets on Beam Therapeutics, with one firm lifting its view by $4 to $45. The firm cited clearer FDA alignment on key programs and the potential for an accelerated review process as key supports for the updated outlook.Anlatı Güncellemesi • Jan 28
BEAM: FDA Alignment And Upcoming Pulmonary Data Will Drive Bullish Repricing
Analysts have nudged their price targets on Beam Therapeutics higher, with the revised fair value estimate moving from about US$45.92 to roughly US$47.21. They cite improved confidence in the company’s FDA alignment on key programs, upcoming BEAM-302 data, and a lower assumed future P/E multiple alongside updated sector views.
Anlatı Güncellemesi • Jan 12
Next Milestones For Beam in 2026.
We now await the JP Morgan health conference. John Evans is set to speak on 13th January.Anlatı Güncellemesi • Dec 09
Beam Therapeutics will revolutionize hospital throughput with breakthrough gene therapy
Beam Therapeutics ($BEAM) has effectively solved the "Gene Therapy Commercialization Problem." While competitors like Vertex ($VRTX) have proven the science works, Beam’s ASH 2025 data confirms it has the superior business model. The new data validates a "Process Efficiency Moat" that structurally lowers Cost of Goods Sold (COGS) and doubles hospital throughput capacity, positioning BEAM-101 as the preferred "Standard of Care" for hospital CFOs. 1.Anlatı Güncellemesi • Dec 06
Beam Rewrites Gene Therapy Playbook with Base Editing Breakthrough
Beam Therapeutics (BEAM) Just Validated the "Best-in-Class" Thesis Headline: Beam Therapeutics: ASH Data Confirms "Best-in-Class" Commercial Profile for Sickle Cell The investment thesis for Beam Therapeutics (NASDAQ: BEAM) has long relied on the promise that Base Editing is not just "another" gene therapy, but a superior industrial platform. The updated N=31 dataset for BEAM-101 (risto-cel) presented at ASH 2025 has now validated this "Best-in-Class" profile with hard data.
Anlatı Güncellemesi • Nov 20
Incredible Buying Opportunity
At the Jefferies London Healthcare Conference, Beam President Pino Ciaramella reinforced the "Best-in-Class" thesis for BEAM-101 in Sickle Cell Disease ahead of the upcoming ASH presentation in December. He asserted that the program maintains a "differentiated manufacturing and clinical profile," highlighting a massive commercial advantage: patients require a median of only one mobilization cycle for cell collection versus the industry standard of two to three.Yeni Anlatı • Oct 27
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Anlatı Güncellemesi • Aug 27
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Beam Therapeutics’ consensus price target has increased to $45.92, reflecting notable improvements in net profit margin and a lower future P/E, signaling enhanced profitability and a more attractive valuation. What's in the News BEAM-101 for sickle cell disease received FDA RMAT and orphan drug designations; updated Phase 1/2 BEACON data show strong, durable increases in fetal hemoglobin, with sustained safety and efficacy for 17 treated patients.Analiz Makalesi • Jul 23
Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • May 29
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now
Key Insights Beam Therapeutics to hold its Annual General Meeting on 4th of June CEO John Evans' total compensation...
Yeni Anlatı • Mar 22
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential.Seeking Alpha • Mar 21
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Summary Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD. BEAM has a long cash runway, and its recent $500 million raise likely secures it into 2028. I believe the recent stock declines make its valuation attractive, given the promising clinical results of their Phase ½ trial. Read the full article on Seeking AlphaSeeking Alpha • Mar 10
Beam Therapeutics: Single-Base Editing Seems To Work
Summary I was looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing therapies, and this morning we have a readout. It was a very small trial: three patients each got 15mg, 30mg, or 60mg of BEAM-302 in a single infusion. Things look good in these early readouts, I have to say. It is of course a small number of patients, but the data make sense, and the numbers clearly seem to be going in the right direction. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 31
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Beam Therapeutics Inc.'s ( NASDAQ:BEAM ) price-to-sales (or "P/S") ratio of 6.2x might make it look like a buy right...Seeking Alpha • Jan 22
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Summary Beam Therapeutics' pipeline, especially BEAM-101 for sickle cell disease, shows promise but remains in early stages with significant risks and high market expectations. Financially, BEAM has a strong cash position, but its high cash burn rate suggests a runway of around 2.5 years, potentially optimistic. The company's valuation is high, reflecting substantial expectations, making it a risky investment despite its long-term potential in gene therapy. While BEAM is worth following for its innovative approaches, I remain cautious about its current price point and recommend patience and risk tolerance. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 20
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Nov 07
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Summary Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market size is projected to grow to $9.84 billion by 2030. Initial data from the phase 1/2 study, using BEAM-302 for the treatment of patients with alpha-1 antitrypsin deficiency, is expected in 2025. Read the full article on Seeking AlphaAnaliz Makalesi • Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Beam Therapeutics Inc.'s ( NASDAQ:BEAM ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a strong buy...Seeking Alpha • Sep 29
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Summary Beam Therapeutics' pipeline, including BEAM-101, BEAM-201, and BEAM-302, shows promise but remains in early stages with no clinical trial data yet available. Despite a strong cash position, Beam's high valuation suggests heavy speculation and high expectations, leading to potential volatility in stock performance. The company's diverse gene therapy approaches target high unmet needs, but success remains uncertain with only preclinical evidence supporting their efficacy. Given the current market cap and speculative nature, I maintain a "Sell" rating, anticipating a more favorable entry point in the future. Read the full article on Seeking AlphaAnaliz Makalesi • Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analiz Makalesi • Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
With a price-to-sales (or "P/S") ratio of 5.7x Beam Therapeutics Inc. ( NASDAQ:BEAM ) may be sending very bullish...Seeking Alpha • Jul 01
Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Summary Beam Therapeutics Inc. is a gene editing company focused on precision genetic medicines through base editing. The company has notable collaborations with Pfizer and other pharma concerns, with several pipeline milestones in 2024. The company is making slow developmental progress, but has some significant longer-term potential and a cash-rich balance sheet for now. An updated analysis around Beam Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Apr 24
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Summary Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with Pfizer, Apellis, Verve, and Sana. Collaboration agreements boosted Beam's revenue in 2023, but future revenue is less predictable due to a lack of product sales. The firm's cash runway is around 2.1 years, suggesting that additional funding may be needed soon, possibly leading to stock dilution. Despite its promising fundamentals, Beam Therapeutics is trading at a relatively high valuation multiple, which detracts from its investment appeal. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
With a price-to-sales (or "P/S") ratio of 5.9x Beam Therapeutics Inc. ( NASDAQ:BEAM ) may be sending very bullish...Analiz Makalesi • Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Beam Therapeutics Inc. ( NASDAQ:BEAM ) defied analyst predictions to release its yearly results, which were ahead of...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$66m |
| Dec 31 2025 | US$6m | US$755k | -US$80m |
| Sep 30 2025 | n/a | n/a | -US$414m |
| Jun 30 2025 | n/a | n/a | -US$398m |
| Mar 31 2025 | n/a | n/a | -US$386m |
| Dec 31 2024 | US$6m | US$716k | -US$377m |
| Sep 30 2024 | n/a | n/a | -US$144m |
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$314m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
Tazminat ve Piyasa: John 'ın toplam tazminatı ($USD 5.82M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.94M ).
Tazminat ve Kazançlar: John 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
John Evans (48 yo)
9.4yrs
Görev süresi
US$5,818,526
Tazminat
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2017. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 9.4yrs | US$5.82m | 0.95% $ 27.6m | |
| President | 6.4yrs | US$3.16m | 0.22% $ 6.3m | |
| Chief Financial Officer | 1.5yrs | US$1.30m | 0.014% $ 397.9k | |
| Chief Legal Officer & Corporate Secretary | 7.2yrs | US$1.97m | 0.11% $ 3.2m | |
| Chief Medical Officer | 5.3yrs | US$2.80m | 0.018% $ 518.4k | |
| Co-Founder | no data | Veri yok | Veri yok | |
| Co-Founder | no data | Veri yok | Veri yok | |
| Co-Founder | no data | Veri yok | Veri yok | |
| Senior VP of Finance | no data | Veri yok | 0.013% $ 389.5k | |
| Chief Technology Officer | no data | Veri yok | Veri yok | |
| Chief Scientific Officer | 3.3yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations & External Communications | no data | Veri yok | Veri yok |
5.8yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: BEAM 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 9.4yrs | US$5.82m | 0.95% $ 27.6m | |
| Independent Director | 4.6yrs | US$465.65k | 0% $ 0 | |
| Independent Lead Director | 8.1yrs | US$495.23k | 0.017% $ 493.8k | |
| Independent Director | 6.7yrs | US$468.15k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$465.65k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$455.65k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$463.15k | 0% $ 0 |
5.4yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BEAM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/14 06:53 |
| Gün Sonu Hisse Fiyatı | 2026/06/12 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Beam Therapeutics Inc. 23 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| William Pickering | Bernstein |
| Alec Stranahan | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |